{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 36 of 122', 'An epinephrine auto-injector device will be provided or prescribed as appropriate to subjects', 'and parents/caregivers who do not have one. The expiration date and record of training on', \"the epinephrine auto-injector device must be documented in the subject's source documents.\", '5.2.6 Unscheduled Visit Procedures', 'Unscheduled visit procedures are listed in each schedule of activities. Other study', 'procedures may be performed as clinically appropriate.', 'Unscheduled visits may be performed anytime to assess or follow up adverse events, or at the', 'request of the subject or investigator. The date and reason for the unscheduled visit must be', 'recorded in the source documentation.', '5.3', 'Early Discontinuation', 'Subjects receiving AR101 treatment: Early treatment discontinuation is defined as', 'permanent cessation of study product administration anytime before completing AR101', 'maintenance treatment at 300 mg/day for approximately 12 months. Subjects who', 'discontinue early will have early discontinuation procedures approximately 14 days after', 'their last dose of AR101 according to the schedule of activities.', 'Subjects with unresolved adverse events at early discontinuation will have safety follow-up', 'per Section 5.5.', 'Temporary treatment interruption (eg, due to an adverse event) will not be considered early', 'discontinuation.', 'Subjects receiving standard of care alone: Early discontinuation of observation is defined as', 'cessation of study participation anytime before the scheduled exit visit. Subjects who', 'discontinue early will have early discontinuation procedures according to the schedule of', 'activities. Subjects with unresolved adverse events at early discontinuation will have safety', 'follow-up per Section 5.5.', 'The primary reasons for early discontinuation of AR101 treatment or observation are listed in', 'Table 5.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 37 of 122', 'Table 5: Primary Reasons for Early Discontinuation', 'Category', 'Reason', 'Comment', 'Protocol/Investigator-Initiated', 'Adverse event or', 'Any intolerable adverse event that cannot be ameliorated using adequate', 'intercurrent illness', 'medical intervention or that in the opinion of the investigator or sponsor', 'may lead to undue risk if AR .101 treatment were continued, such as the', 'following:', 'Life-threatening symptoms (CoFAR grade 4), including anaphylaxis', 'resulting in hypotension, neurologic compromise, or mechanical', 'ventilation secondary to study treatment or food challenge.', 'Severe dose-related allergic hypersensitivity symptoms (CoFAR', 'grade 3) that require intensive therapy (per investigator assessment, but', 'may include interventions such as IV epinephrine, intubation, or', 'admission to an intensive care unit) or are recurrent.', 'Poor control or persistent activation of secondary atopic disease', '(eg, atopic dermatitis, asthma).', 'Development of biopsy-documented eosinophilic esophagitis.', 'Any adverse event that meets the early discontinuation criteria for study', 'product tolerability or delays as follows:', 'Tolerability of study product:', '- Moderate or dose-limiting symptoms at < 3 mg or severe symptoms', 'at any dose on initial dose-escalation day 1 and 2', '- The dose was withheld for > 4 weeks for chronic or recurrent', 'gastrointestinal adverse events at VI 20 mg/day', '- Unable to reach the 300 mg/day dose within 40 weeks of up-dosing', '- Unable to tolerate at least 300 mg of peanut protein at the OLFC', 'Use of rescue medications:', '- Treatment with epinephrine, beta-agonist, oxygen, IV fluids,', '> 2 doses of antihistamines, and/or glucocorticosteroids at any', 'AR101 dose (including 6 mg) on initial dose-escalation days 1 and 2', '- Treatment with > 2 doses of epinephrine for dose-related allergy', 'symptoms anytime', 'Dose adjustment of study product:', '- Unable to escalate the dose level after 3 consecutive failed attempts', 'with at least 2 weeks between each escalation attempt', '- Unable to tolerate 3 attempts at dose reduction after the occurrence', 'of mild or moderate allergy symptoms, or unable to tolerate', '1 attempt at dose reduction after the occurrence of severe symptoms', '- Missed > 15 consecutive days of study product dosing due to', 'medically indicated circumstances (eg, as part of the treatment for', 'an intercurrent adverse event); missed doses per dose adjustment', 'guidelines in Section 8.5.3.2 are allowed.', 'Use of prohibited', 'Prohibited concomitant medications are listed in Section 7.4.', 'medication', 'Pregnancy', 'Pregnancy will be followed to delivery or until termination of the', 'pregnancy (Section 8.5.7.2).', 'Death']\n\n###\n\n", "completion": "END"}